Dementia disorders are today considered to be a major driver of costs in health care and social systems and worrying estimates of future dementia prevalence have been presented. It is of great interest for policy makers to have an estimate of dementia disorders’ contribution to global social and health care costs, particularly in light of the demographic prognoses. The worldwide costs of dementia were estimated from prevalence figures for different regions, and cost-of-illness studies from key countries using a model based on the relationship between direct costs of care per demented and the gross domestic product per capita in each country. The worldwide direct costs for dementia in 2003 are estimated at 156 billion USD in the main scenario based on a worldwide prevalence of 27.7 million demented persons (sensitivity analysis: 129–159 billion USD). Ninety-two percent of the costs are found in the advanced economies with 38% of the prevalence. Although there are several sources of uncertainty, it is obvious that the worldwide costs are substantial and the expected increase in elderly people in the developing countries presents a great challenge.
© 2006 S. Karger AG, Basel
- Worldwide direct costs
- Worldwide prevalence
- Cost of illness
- Schneider EL, Guralnik JM: The aging of America. Impact on health care costs. JAMA 1990;263:2335–2340.
- Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, et al: The economic burden of Alzheimer’s disease care. Health Aff (Millwood) 1993;12:164–176.
- Jonsson B, Jonsson L, Wimo A: Cost of dementia; in May M, Sartorius N (eds): Dementia. WPA Series Evidence and Experience in Psychiatry. London, Wiley & Sons, 2000, pp 335–363.
- Wimo A, Winblad B, Aguero Torres H, von Strauss E: The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003;17:63–67.
- Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J: Cost of disorders of the brain in Europe. Eur J Neurol 2005;12(suppl 1):1–27.
- Jacobzone S, Cambois E, Chaplain E, Robine J: Long term care services to older people, a perspective on future trends: the impact of an improved health of older persons. Report No AWP 4.2. Paris, OECD, 1998.
- Fratiglioni L, Rocca WA: Epidemiology of dementia; in Boller F, Cappa SF (eds): Handbook of Neuropsychology, ed 2. Amsterdam, Elsevier, 2001, pp 193–215.
- UN: World population prospects: The 1998 revision. World population 1950–2050. New York, United Nations, 1998.
- Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al: Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(suppl 5):S4–S9.
- Hofman A, Rocca WA, Brayne C, Breteler MM, Clarke M, Cooper B, et al: The prevalence of dementia in Europe: a collaborative study of 1980–1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol 1991;20:736–748.
- Rice DP, Hodgson TA, Kopstein AN: The economic costs of illness: a replication and update. Health Financing Rev 1985;7:61–80.
- Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR: Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997;11:159–168.
- World Economic Outlook: International Monetary Fund. http://www.imf.org/external/pubs/ft/weo/2004/02/data/index.htm.
- World bank classification of economies, 2005. http://www.wordlbank.org/data/countryclass/classgroups.htm.
- Håkansson S: Different ways of organizing and financing health care; in Wimo A, Jönsson B, Karlsson G, Winblad B (eds): Health Economics of Dementia. London, Wiley & Sons, 1998, pp 67–97.
- Gerdtham UG, Lothgren M: On stationarity and cointegration of international health expenditure and GDP. J Health Econ 2000;19:461–475.
- International Monetary Fund: World Economic Outlook Database, 2004. http://www.imf.org/external/pubs/ft/weo/2004/02/data/index.htm#countryinfo.
- International Labour Organization: Laborsta Internet, 2004. http://laborsta.ilo.org/.
- Ernst RL, Hay JW: The US economic and social costs of Alzheimer’s disease revisited. Am J Public Health 1994;84:1261–1264.
- Manton KG, Corder LS, Clark R: Estimates and projections of dementia-related service expenditures; in Suzman R, Singer B, Manton KG (eds): Forecasting the Health of the Oldest Old. New York, Springer, 1993, pp 207–238.
- Ostbye T, Crosse E: Net economic costs of dementia in Canada. CMAJ 1994;151:1457–1464.
- Hux MJ, O’Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S: Relation between severity of Alzheimer’s disease and costs of caring. CMAJ 1998;159:457–465.
- McNamee P, Bond J, Buck D: Costs of dementia in England and Wales in the 21st century. Br J Psychiatry 2001;179:261–266.
- Smith KA, Shah A: The prevalence and costs of psychiatric disorders and learning disabilities. Br J Psychiatry 1995;166:9–18.
- Holmes J, Pugner K, Phillips R, Dempsey G, Cayton H: Managing Alzheimer’s disease: the cost of care per patient. Br J Health Care Management 1998;4:332–337.
- Wimo A, Karlsson G, Sandman PO, Corder L, Winblad B: Cost of illness due to dementia in Sweden. Int J Geriatr Psychiatry 1997;12:857–861.
- Schulenberg J, Schulenberg I: Cost of treatment and cost of care for Alzheimer’s disease in Germany; in Wimo A, Jonsson B, Karlsson G, Winblad B (eds): The Health Economics of Dementia. London, Wiley & Sons, 1998, pp 217–230.
- Kronborg Andersen C, Sogaard J, Hansen E, Kragh-Sorensen A, Hastrup L, Andersen J, et al: The cost of dementia in Denmark: the Odense Study. Dement Geriatr Cogn Disord 1999;10:295–304.
- Cavallo MC, Fattore G: The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy. Alzheimer Dis Assoc Disord 1997;11:184–190.
- Koopmanschap MA, Polder JJ, Meerding WJ, Bonneux L, van der Maas PJ: Costs of dementia in the Netherlands; in Wimo A, Jonsson B, Karlsson G, Winblad B (eds): The Health Economics of Dementia. London, Wiley & Sons, 1998, pp 207–216.
- O’Shea E, O’Reilly S: The economic and social cost of dementia in Ireland. Int J Geriatr Psychiatry 2000;15:208–218.
- WHO: World Health report, 2004. www.who.int/whr/2004/annex/topic/annex3.xls.
- Mathers C, Stein C, Ma Fat D, Rao C, Inoue M, Tomijima N, et al: Global burden of disease 2000. Version 2: methods and results. Global Programme on Evidence for Health Policy Discussion Paper No 50. Geneva, WHO, 2002.
- Prince M: Care arrangements for people with dementia in developing countries. Int J Geriatr Psychiatry 2004;19:170–177.
- Kabir ZN, Szebehely M, Tishelman C: Support in old age in the changing society of Bangladesh. Ageing Soc 2002;22:615–636.
- Logminiene Z, Norkus A, Valius L: Direct and indirect diabetes costs in the world. Medicina (Kaunas) 2004;40:16–26.
Dr. Anders Wimo
SE–820 75 Harmånger (Sweden)
Fax +46 652 71261, E-Mail Anders.Wimo@neurotec.ki.se
Accepted: October 18, 2005
Published online: January 9, 2006
Number of Print Pages : 7
Number of Figures : 0, Number of Tables : 5, Number of References : 36
Dementia and Geriatric Cognitive Disorders
Vol. 21, No. 3, Year 2006 (Cover Date: February 2006)
Journal Editor: Chan-Palay, V. (New York, N.Y.)
ISSN: 1420–8008 (print), 1421–9824 (Online)
For additional information: http://www.karger.com/DEM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.